慢性肺心病患者血小板功能的研究

目的研究慢性肺心病患者血小板功能的变化。方法将研究对象分为肺心病急性发作期组、肺心病缓解期组和正常对照组,采用放射免疫分析法、玻璃球旋转法、比浊法等分别测定各组血浆血栓素B2（TXB2）、6-酮前列腺素F1a（6－K－PGF1a）和血小板粘附率（PAdT）、血小板聚集率（PAgT）及血小板激活因子（PAF）水平。结果慢性肺心病急性发作期组TXB2、6－K－PGF1a、TXB2／6－K－PGF1a比值和PAdT、PAgT及PAF测定值分别为204．76±3589pg／ml、49.08±1438pg／ml、4.11±1.72和42±11％、21±8％和89.05±41.76ng／ml。在缓解期组,上述各项测定值分别为138．34±20.41pg／ml、66．25±17.12pg／ml、2．08±0.97和39±12％、46±14％和56．82±34.14ng／ml。而在正常对照组则分别为76.05±16．24pg／ml、88.65±21.87pg／ml、0．84±0．23和26±7％、35±12％和47．94±32．48ng／ml。结论慢性肺心病患者体内血小板被激活．血小板粘附、聚集等功能增强。     

疏肝起萎汤配合夫妻性感集中训练疗法治疗心因性勃起功能障碍147例疗效观察

目的:观察疏肝起萎汤配合夫妻性感集中训练疗法治疗心因性勃起功能障碍的临床疗效。方法:将406例患者随机分为3组,治疗组147例采用疏肝起萎汤(由柴胡、枳壳、白芍、淫羊藿、蜈蚣、川芎、陈皮、炙甘草组成)配合夫妻性感集中训练疗法治疗;对照Ⅰ组132例采用疏肝起萎汤治疗;对照Ⅱ组127例采用家庭性感集中训练疗法治疗。观察3组综合疗效和症状改善情况。结果:治疗组痊愈99例,好转37例,痊愈率67.35％,总有效率92.52％;对照Ⅰ组痊愈49例,好转34例,痊愈率37.12％,总有效率62.88％;对照Ⅱ组痊愈53例,好转36例,痊愈率41.70％,总有效率70.08％。治疗组与对照Ⅰ组、对照Ⅱ组痊愈率、总有效率比较,差异均有显著性意义(P<0.05)。结论:疏肝起萎汤配合夫妻性感集中训练疗法治疗心因性勃起功能障碍,疗效确切。     

Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression

The degradation of the basement membrane by matrix-metalloproteinase(MMP) and serine protease is a critical pointin tumor invasion and metastasis. We measured theactivity of MMP-9 from 28 normal, 12 benignand 126 breast cancer tissues using gelatin zymographywith an image analysis system. ProMMP-9 was expressedin 17.5% of the cancer patients compared to2.5% in 40 non-cancerous tissues (p=0.014).The mature form of MMP-9 (82 kD) wasexpressed only in T2–T4 stages. During the earlyphase of breast cancer (DCIS and T1 stage)progression, only production of proMMP-9 increased. However, asthe cancer grew or invaded skin (T2–T4), orwith lymphovascular permeation, both production and activation ofMMP-9 increased. In conclusion, proMMP-9 production was themain cause of increased MMP-9 activity during theearly phase, while both production and activation increasedin the late phase of breast cancer.     

高压氧预处理对宫内缺血缺氧大鼠脑组织及血浆神经肽Y含量的影响

目的 :探讨高压氧 (HBO)预处理对宫内缺血缺氧大鼠脑组织及血浆神经肽Y含量的影响。方法 :采用放射免疫法测定 2 5例正常胎鼠 (对照组 )、2 7例宫内缺血缺氧胎鼠 (缺血缺氧组 )及 1 9例经高压氧预处理宫内缺血缺氧胎鼠 (HBO组 )中枢及外周血神经肽Y的含量。结果 :HBO组胎鼠脑及外周血神经肽Y的含量分别为 52 .64±1 2 .1 6pg/mg及 1 99.51± 49.36ng/L ,缺血缺氧组胎鼠脑及外周血神经肽Y的含量分别为87.2 5± 2 3.63pg/mg及 2 51 .53±55 .2 8ng/L ,对照组胎鼠神经肽Y含量为 48.63± 1 0 .72pg/mg及 1 4 7.35± 31 .49ng/L ;与对照组相比 ,缺血缺氧组胎鼠中枢及外周神经肽Y含量均显著升高 (P <0 .0 1 ) ;HBO组神经肽Y含量显著低于缺血缺氧组 (P <0 .0 5)。结论 :神经肽Y与围生期缺血缺氧的发生密切相关 ,HBO预处理具有改善宫内缺血缺氧的作用 ,其机理可能与抑制神经肽Y的生成有关     

卡托普利对心脏成纤维细胞端粒长度的作用研究

目的探讨卡托普利对心脏成纤维细胞端粒长度的影响。方法使用流式荧光原位杂交法（Flow—Fish）检测成纤维细胞端粒长度的变化。结果经过卡托普利处理过的成纤维细胞端粒明显缩短。结论本研究通过Flow—Fish法证实了卡托普利能缩短成纤维细胞端粒的长度，引起心脏成纤维细胞衰老的发生，从而抑制CFs的增殖。     

Smad4和Smad7在人脑胶质瘤中的表达及意义

目的探讨Smad4和Smad7在人脑胶质瘤中的表达及意义.方法采用免疫组化方法,对临床经过石蜡包埋的30例胶质瘤和8例正常脑组织标本进行定位和定性检测.结果 Smad4 和 Smad7蛋白在胶质瘤中有不同程度的表达,在正常脑组织、低、高级别胶质瘤中Smad4的阳性表达分别为44.80±16.19,25.81±9.48,6.73±3.71,P<0.05.Smad7的阳性表达分别为6.69±3.86,18.22±7.84,41.95±17.27,P<0.05.差别均有显著意义.且Smad4与Smad7的表达水平呈负相关,r＝-0.82,P<0.01.结论 Smad4随胶质瘤的病理分级增高阳性表达降低,对胶质瘤的进展有抑制作用.Smad7则相反,可能参与了胶质瘤的恶性进展.     

异甘草素对人前列腺癌细胞体外增殖的抑制作用

目的:观察异甘草素(ISL)对人前列腺癌细胞体外增殖的抑制作用。方法:采用MTT法测定细胞增殖。结果:ISL浓度依赖性(0~20μm)抑制人前列腺癌细胞增殖,IC50为12.58μm,且呈时间依赖性,ISL20μm作用3天时的抑制率为85.26%。结论:异甘草素能有效地抑制前列腺癌细胞的增生,异甘草素有可能成为一种治疗前列腺癌的新药。     

Louki Zupa decoction attenuates the airway inflammation in acute asthma mice induced by ovalbumin through IL-33/ST2-NF-κB/GSK3β/mTOR signalling pathway

ContextAsthma is a common respiratory system disease. Louki Zupa decoction (LKZP), a traditional Chinese medicine, presents a promising efficacy against lung diseases.ObjectiveTo investigate the pathogenic mechanism of asthma and reveal the intervention mechanism of LKZP.Materials and methodsForty-eight female Balb/c mice were randomly divided into 6 groups: normal control group (NC), ovalbumin (OVA)/saline asthma model group, OVA/LL group, OVA/LM group, OVA/LH group and OVA/DEX group (n = 8 per group). The asthmatic mice were modelled through intraperitoneal injecting and neutralizing OVA. LKZP decoction was administrated by gavage at the challenge stage for seven consecutive days (2.1, 4.2 and 8.4 g/kg/day). We investigated the change in lung function, airway inflammation, mucus secretion and TH-1/TH-2-related cytokines. We further verify the activated status of the IL-33/ST2/NF-κB/GSK3β/mTOR signalling pathway.ResultsLKZP was proved to improve asthmatic symptoms, as evidenced by the down-regulated airway resistance by 36%, 58% and 53% (p < 0.01, p < 0.001 vs. OVA/saline group), up-regulated lung compliance by 102%, 114% and 111%, decreased airway inflammation and mucus secretion by 33%, 40% and 33% (p < 0.001 vs. OVA/saline group). Moreover, the content of cytokines in BALF related to airway allergy (such as IgE) and T helper 1/T helper 2 cells (like IL-2, IL-4, IL-5, IL-13, TNF-α and IFN-γ), were also markedly reduced by 13–65% on LKZP intervention groups compared with model group. Mechanistic research revealed that the IL-33/ST2-NF-κB/GSK3β/mTOR signalling pathway was activated in the OVA/saline group and LKZP significantly down-regulated this pathway.Discussion and conclusionLKZP improves lung function, airway inflammation, mucus secretion and correct immune imbalance by intervening with the IL-33/ST2-NF-κB/GSK3β/mTOR signalling pathway, presenting a promising therapeutic choice for asthma.     

向日葵胰蛋白酶抑制剂SFTI的合成及酶抑制动力学研究

目的 考察合成的向日葵胰蛋白酶抑制剂的抑制效果,计算其抑制常数Ki.方法 采用Fmoc固相化学合成方法,反相柱纯化后用CytofluorTM微孔板发光检测仪测定向日葵胰蛋白酶抑制剂的抑制常数.结果与结论 向日葵胰蛋白酶抑制剂的Ki值为2.2nM±0.5(n=8),抑制效果良好.     

Triple Therapy-Based on Tegoprazan,a New Potassium-Competitive Acid Blocker,for First-Line Treatment of Helicobacter pylori Infection: A Randomized,Double-Blind,Phase III,Clinical Trial

Background/AimsWe examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication.MethodsA randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)-based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating H. pylori. The primary endpoint was the H. pylori eradication rate. Subgroup analyses were performed according to the cytochrome P450 (CYP) 2C19 genotype, the minimum inhibitory concentration (MIC) of amoxicillin and clarithromycin, and underlying gastric diseases.ResultsIn total, 350 H. pylori-positive patients were randomly allocated to the TPZ or LPZ group. The H. pylori eradication rates in the TPZ and LPZ groups were 62.86% (110/175) and 60.57% (106/175) in an intention-to-treat analysis and 69.33% (104/150) and 67.33% (101/150) in a per-protocol analysis (non-inferiority test, p=0.009 and p=0.013), respectively. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in eradication rate. Both first-line triple therapies were well-tolerated with no notable differences.ConclusionsTPZ is as effective as proton pump inhibitor-based triple therapy and is as safe as first-line H. pylori eradication therapy but does not overcome the clarithromycin resistance of H. pylori in Korea (ClinicalTrials.gov identifier {"type":"clinical-trial","attrs":{"text":"NCT03317223","term_id":"NCT03317223"}}NCT03317223).